Esperion Therapeutics (ESPR) Other Gross PP&E Adjustments: 2018-2025
Historic Other Gross PP&E Adjustments for Esperion Therapeutics (ESPR) over the last 6 years, with Sep 2025 value amounting to -$3.3 million.
- Esperion Therapeutics' Other Gross PP&E Adjustments rose 46.56% to -$3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.8 million, marking a year-over-year increase of 13.47%. This contributed to the annual value of -$29.2 million for FY2024, which is 4.17% down from last year.
- Latest data reveals that Esperion Therapeutics reported Other Gross PP&E Adjustments of -$3.3 million as of Q3 2025, which was up 21.45% from -$4.2 million recorded in Q2 2025.
- In the past 5 years, Esperion Therapeutics' Other Gross PP&E Adjustments ranged from a high of -$730,000 in Q3 2022 and a low of -$29.2 million during Q4 2024.
- In the last 3 years, Esperion Therapeutics' Other Gross PP&E Adjustments had a median value of -$5.0 million in 2025 and averaged -$8.8 million.
- In the last 5 years, Esperion Therapeutics' Other Gross PP&E Adjustments soared by 84.87% in 2022 and then plummeted by 563.26% in 2024.
- Esperion Therapeutics' Other Gross PP&E Adjustments (Quarterly) stood at -$21.9 million in 2021, then decreased by 12.07% to -$24.6 million in 2022, then decreased by 14.30% to -$28.1 million in 2023, then declined by 4.17% to -$29.2 million in 2024, then spiked by 46.56% to -$3.3 million in 2025.
- Its last three reported values are -$3.3 million in Q3 2025, -$4.2 million for Q2 2025, and -$5.0 million during Q1 2025.